179 results on '"Sanyal, Arun J."'
Search Results
2. Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis
3. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis
4. Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
5. acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study
6. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study
7. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study
8. Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study
9. Terlipressin Treatment Is Associated With Reversal of Hepatorenal Syndrome in Patients With Alcoholic Hepatitis
10. aMAP Score and Its Combination With Liver Stiffness Measurement Accurately Assess Liver Fibrosis in Chronic Hepatitis B Patients
11. Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort
12. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review
13. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis
14. The Spectrum and Impact of Metabolic Dysfunction in MAFLD: A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals
15. Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study
16. Noninvasive Assessment of Liver Fibrosis in NAFLD
17. Artificial Intelligence Improves Pathologist Agreement for Fibrosis Scores in Nonalcoholic Steatohepatitis Patients
18. Design of a multicenter randomized clinical trial for treatment of Alcohol-Associated Hepatitis
19. Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials
20. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD
21. Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review
22. A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease
23. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis
24. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
25. A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis
26. Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis
27. Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease
28. Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study
29. Burden of Disease due to Nonalcoholic Fatty Liver Disease
30. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage
31. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease
32. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
33. Pegozafermin Added to Background GLP-1 Therapy Led to Greater Improvement in Non-invasive Markers of Liver Fat, Injury and Fibrosis as well as Glycemic Control in NASH Patients with F2/F3 Fibrosis at 24 weeks: A Posthoc Analysis from ENLIVEN
34. Pegozafermin, a FGF21 Analog, for the Treatment of Non-alcoholic Steatohepatitis (NASH) Patients with F2/F3 Fibrosis
35. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
36. The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease
37. Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children
38. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome
39. Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis
40. Chapter 31 - Pharmacologic therapies in metabolic syndrome with special reference to non-alcoholic fatty liver disease
41. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
42. Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease
43. In Patients With Cirrhosis, Driving Simulator Performance Is Associated With Real-life Driving
44. Discordant association of nonalcoholic fatty liver disease with lipoprotein(a) and markers of atherogenic dyslipidemia
45. Validation of EncephalApp, Smartphone-Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy
46. Endoscopic Diagnosis and Therapy in Gastroesophageal Variceal Bleeding
47. Cognitive Reserve Is a Determinant of Health-related Quality of Life in Patients With Cirrhosis, Independent of Covert Hepatic Encephalopathy and Model for End-Stage Liver Disease Score
48. Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein Profile
49. Effects of Obstructive Sleep Apnea on Sleep Quality, Cognition, and Driving Performance in Patients With Cirrhosis
50. Validation of Noninvasive Methods for Detecting Hepatic Steatosis in Patients With Human Immunodeficiency Virus Infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.